iBio Inc (IBIO)
2.55
-0.01
(-0.39%)
USD |
NYAM |
Nov 12, 16:00
2.545
0.00 (0.00%)
After-Hours: 20:00
iBio Research and Development Expense (Quarterly): 1.14M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.14M |
| March 31, 2024 | 0.904M |
| December 31, 2023 | 1.535M |
| September 30, 2023 | 1.606M |
| June 30, 2023 | 2.356M |
| March 31, 2023 | 2.644M |
| December 31, 2022 | 2.779M |
| September 30, 2022 | 2.548M |
| June 30, 2022 | 3.562M |
| March 31, 2022 | 3.272M |
| December 31, 2021 | 1.859M |
| September 30, 2021 | 1.134M |
| June 30, 2021 | 3.097M |
| March 31, 2021 | 2.162M |
| December 31, 2020 | 2.374M |
| September 30, 2020 | 1.862M |
| June 30, 2020 | 0.583M |
| March 31, 2020 | 1.095M |
| December 31, 2019 | 0.888M |
| September 30, 2019 | 0.977M |
| June 30, 2019 | 1.624M |
| March 31, 2019 | 1.453M |
| December 31, 2018 | 1.273M |
| September 30, 2018 | 1.124M |
| June 30, 2018 | 1.042M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.966M |
| December 31, 2017 | 0.993M |
| September 30, 2017 | 0.985M |
| June 30, 2017 | 1.112M |
| March 31, 2017 | 1.136M |
| December 31, 2016 | 1.049M |
| September 30, 2016 | 0.82M |
| June 30, 2016 | 0.853M |
| March 31, 2016 | 1.048M |
| December 31, 2015 | 0.704M |
| September 30, 2015 | 0.551M |
| June 30, 2015 | 0.764M |
| March 31, 2015 | 0.815M |
| December 31, 2014 | 0.731M |
| September 30, 2014 | 1.185M |
| June 30, 2014 | -0.589M |
| March 31, 2014 | 0.343M |
| December 31, 2013 | 0.585M |
| September 30, 2013 | -0.489M |
| June 30, 2013 | 0.967M |
| March 31, 2013 | 0.631M |
| December 31, 2012 | 0.656M |
| September 30, 2012 | 1.177M |
| June 30, 2012 | 1.055M |
| March 31, 2012 | 1.307M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.583M
Minimum
Jun 2020
3.562M
Maximum
Jun 2022
1.968M
Average
1.862M
Median
Sep 2020
Research and Development Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.009M |
| Palatin Technologies Inc | 4.672M |
| Theriva Biologics Inc | 2.953M |
| Oragenics Inc | 0.9068M |
| Nanoviricides Inc | 1.182M |